Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 15:18:5289-5307.
doi: 10.2147/IJN.S418588. eCollection 2023.

How Combined Macrolide Nanomaterials are Effective Against Resistant Pathogens? A Comprehensive Review of the Literature

Affiliations
Review

How Combined Macrolide Nanomaterials are Effective Against Resistant Pathogens? A Comprehensive Review of the Literature

Ebrahim Abdela Siraj et al. Int J Nanomedicine. .

Abstract

Macrolide drugs are among the broad-spectrum antibiotics that are considered as "miracle drugs" against infectious diseases that lead to higher morbidity and mortality rates. Nevertheless, their effectiveness is currently at risk owing to the presence of devastating, antimicrobial-resistant microbes. In view of this challenge, nanotechnology-driven innovations are currently being anticipated for promising approaches to overcome antimicrobial resistance. Nowadays, various nanostructures are being developed for the delivery of antimicrobials to counter drug-resistant microbial strains through different mechanisms. Metallic nanoparticle-based delivery of macrolides, particularly using silver and gold nanoparticles (AgNPs & AuNPs), demonstrated a promising outcome with worthy stability, oxidation resistance, and biocompatibility. Similarly, macrolide-conjugated magnetic NPs resulted in an augmented antimicrobial activity and reduced bacterial cell viability against resistant microbes. Liposomal delivery of macrolides also showed favorable synergistic antimicrobial activities in vitro against resistant strains. Loading macrolide drugs into various polymeric nanomaterials resulted in an enhanced zone of inhibition. Intercalated nanomaterials also conveyed an outstanding macrolide delivery characteristic with efficient targeting and controlled drug release against infectious microbes. This review abridges several nano-based delivery approaches for macrolide drugs along with their recent achievements, challenges, and future perspectives.

Keywords: drug resistance; macrolide nano-delivery; macrolides; nanomedicine.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Multiple resistance mechanism of bacteria to MDR pathogen.
Figure 2
Figure 2
Different mechanisms of action of NPs in bacterial.
Figure 3
Figure 3
Diagrammatic explanation of different Nano carriers.
Figure 4
Figure 4
General mechanism of action for silver nanoparticles.
Figure 5
Figure 5
Proposed mechanism of action of AZT-D-LPs.

References

    1. Imran M, Jha SK, Hasan N, et al. Overcoming multidrug resistance of antibiotics via nanodelivery systems. Pharmaceutics. 2022;14(3):1–25. doi:10.3390/pharmaceutics14030586 - DOI - PMC - PubMed
    1. Fareed N, Nisa S, Bibi Y, et al. Green synthesized silver nanoparticles using carrot extract exhibited strong antibacterial activity against multidrug resistant bacteria. J King Saud Univ. 2023;35(2):102477. doi:10.1016/j.jksus.2022.102477 - DOI
    1. Valizadeh H, Mohammadi G, Ehyaei R, Milani M, Azhdarzadeh M, Lotfipour F. Antibacterial activity of clarithromycin loaded PLGA nanoparticles. Int J Pharm Sci. 2012;2012:63–68. - PubMed
    1. Abou DH, Abbas HS. Antimicrobial activity of biosynthesized Cuo / Se nanocomposite against Helicobacter pylori. Arab J Chem. 2023;16(9):105095. doi:10.1016/j.arabjc.2023.105095 - DOI
    1. Alavi M, Rai M. Expert review of anti-infective therapy recent advances in antibacterial applications of metal nanoparticles (MNPs) and metal nanocomposites (MNCs) against multidrug- resistant (MDR) bacteria. Expert Rev Anti Infect Ther. 2019;17(6):419–428. doi:10.1080/14787210.2019.1614914 - DOI - PubMed